The company has delivered a perfect four-quarter earnings beat streak with an exceptional average positive surprise and extraordinary free cash flow conversion, but revenue is declining and the current price offers thin reward against meaningful downside — keeping conviction limited despite the encouraging earnings track record.
Thesis pillars
- Perfect Earnings Beat Streak→Stable
- Declining Revenue Structural Headwind→Stable
- Exceptional Free Cash Flow Conversion→Stable
- +1 more pillar — see the Why tab for full reasoning
ICU Medical, Inc. (ICUI) Stock Analysis
Range Bound setup · Catalyst-Driven edge
Healthcare · Medical Instruments & Supplies
Sell if holding. At $156.03, A.R:R 1.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 7.8%; Concentration risk — Supplier: single supplier.
ICU Medical develops, manufactures, and sells medical devices for infusion therapy, vascular access, and vital care, serving acute care hospitals, ambulatory clinics, and long-term care facilities in over 100 countries. Revenue flows through direct sales and distributors... Read more
Sell if holding. At $156.03, A.R:R 1.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 7.8%; Concentration risk — Supplier: single supplier. Chart setup: RSI 55 mid-range, Bollinger mid-band. Score 4.9/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 29d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-10-08Recent Developments — ICU Medical, Inc.
Latest news
- NEWS ICU Medical Q1 2026 Earnings: Strong EPS Beat Drives Stock Up 2.67% - Revenue Inflection Point - dars.gov.et — dars.gov.et positive
- NEWS ICU Medical Earnings: What To Look For From ICUI - StockStory — StockStory neutral
- NEWS ICU Medical (ICUI) Reports Q2: Everything You Need To Know Ahead Of Earnings - StockStory — StockStory neutral
- NEWS ICU Medical (ICUI) Reports Q2: Everything You Need To Know Ahead Of Earnings - TradingView — TradingView neutral
- NEWS Icui stock reaches 52-week high at 162.89 USD - Investing.com — Investing.com positive
Generated 2026-10-08T11:47:04Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWCustomersingle distributor18%10-K Item 1: 'we had worldwide net sales to a single distributor of 18%, 18%, and 16% of consolidated net sales, respectively'
- HIGHSuppliersingle supplier10-K Item 1: 'Certain components and raw materials are available only from a single supplier'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $156.03, A.R:R 1.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 7.8%; Concentration risk — Supplier: single supplier. Chart setup: RSI 55 mid-range, Bollinger mid-band. Prior stop was $146.87. Score 4.9/10, moderate confidence.
Take-profit target: $168.24 (+7.8% upside). Prior stop was $146.87. Stop-loss: $146.87.
Concentration risk — Supplier: single supplier; Thin upside margin: 7.8%; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6).
ICU Medical, Inc. trades at a P/E of 134.2 (forward 16.6). TrendMatrix value score: 6.3/10. Verdict: Sell.
13 analysts cover ICUI with a consensus score of 4.3/5. Average price target: $193.
What does ICU Medical, Inc. do?ICU Medical develops, manufactures, and sells medical devices for infusion therapy, vascular access, and vital care,...
ICU Medical develops, manufactures, and sells medical devices for infusion therapy, vascular access, and vital care, serving acute care hospitals, ambulatory clinics, and long-term care facilities in over 100 countries. Revenue flows through direct sales and distributors globally, with a single distributor accounting for 18% of consolidated net sales in 2025. In May 2025, ICU closed a transaction transferring its IV Solutions business to a joint venture with Otsuka Pharmaceutical Factory America, retaining a 40% stake.